Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases. - Wikidata - wikimedia - TriplyDB

Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.

Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.

http://www.wikidata.org/entity/Q38668948

about

Nesfatin-1 protects dopaminergic neurons against MPP+/MPTP-induced neurotoxicity through the C-Raf-ERK1/2-dependent anti-apoptotic pathway Antidiabetic Drugs in Alzheimer's Disease: Mechanisms of Action and Future Perspectives.Exendin-4 antagonizes Aβ1-42-induced attenuation of spatial learning and memory ability Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.Obesity as a risk factor for Alzheimer's disease: weighing the evidence.Semaglutide seems to be more effective the other GLP-1Ras.Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation.Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review.Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases-An Overview of Imaging Studies.

P2860

Q30835631-01B56CC8-645E-4253-AE6F-B3F4067E87CA Q33800802-718B13F6-9730-49F2-89E3-23E759F29707 Q37406399-7C347706-C234-4E5D-98B7-9D41D33688C4 Q39042377-A2345FB6-12A1-47AB-9B87-6869BF869657 Q41986529-55297959-F106-4D80-810F-0446FAE36730 Q47114286-806CDA00-CDB2-4A70-9C88-120765AC287F Q48024722-AA82DBEA-FDDB-4F21-9AA1-D41A5ED5833D Q48488584-8088ECEC-1D49-4C27-9996-7DA49129D185 Q53685113-3CB9DB3D-A755-40CA-91D7-210E19E61685 Q55004525-CD363E39-0863-4FB4-A3BC-E2193149DAAE

P2860

Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.

http://www.wikidata.org/entity/Q38668948

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Novel GLP-1 (Glucagon-Like Pep ...... er Neurodegenerative Diseases.

@en

type

label

Novel GLP-1 (Glucagon-Like Pep ...... er Neurodegenerative Diseases.

@en

prefLabel

Novel GLP-1 (Glucagon-Like Pep ...... er Neurodegenerative Diseases.

@en

P1433

Q38668948-14218905-26A8-4B9A-B6F8-632C8B3C54C8

P1476

Q38668948-5CE0CB27-BD2A-4748-84DF-BB46B6C9D401

P2093

Q38668948-5F0C3259-A2F8-4AD1-B311-3B5A5DF33858

Q38668948-71CDEF48-4E7C-4BE3-B0AF-ED3426604FC5

P2860

Q38668948-01AF10AD-3FB7-4D0F-BB52-82AC5FD98B9A

Q38668948-09365328-0BB7-4027-84C4-14126BD91784

Q38668948-098F7DDD-3874-4B63-AAE8-372EA69EDE52

Q38668948-0F8DF383-10EE-4D6F-93FD-7F08EE7C1118

Q38668948-162B5357-7EB4-4202-B9B0-ACCA150A10D9

Q38668948-16A98476-314A-4BEA-8192-E9B2E9821ADA

Q38668948-1E51360F-EC1D-49F7-857F-7D2A048DB787

Q38668948-26224578-91AF-4201-8DFE-305D82E4D07B

Q38668948-26A34F23-B2EC-4440-B4B1-C4533C49499E

Q38668948-27438FFF-BB41-4D70-A588-458C7DA114F1

P2888

Q38668948-2E04EA30-C450-48C2-AACF-581B49BBA252

P304

Q38668948-01BFD1C4-3C24-4798-B232-8B70E4A2567E

P31

Q38668948-5FAAF3DF-603D-4E5F-8559-91FFDFE9955C

P356

Q38668948-6C5EB474-FE90-4B14-A955-B59AA1F09719

P433

Q38668948-76F87FED-842D-416E-B1C6-21E38195382D

P478

Q38668948-F91018AE-7304-466B-9747-213C4A105AB0

P577

Q38668948-667EED6A-C3EB-4DB3-A286-44265C5BE3B0

P5875

Q38668948-966FEB0B-7B83-4F8F-BAE7-261434646E90

P698

Q38668948-63DD350E-7A93-4682-A053-3C062C18700A

P921

Q38668948-C7058B00-1735-4114-95A0-F6A68DC39E5D

Q38668948-EECCD824-E31C-44E8-97E5-66AF025F57AA

P356

S40263-015-0301-8

P1433

P1476

Novel GLP-1 (Glucagon-Like Pep ...... er Neurodegenerative Diseases.

@en

P2093

Paul Edison

http://www.w3.org/2001/XMLSchema#string

Valeria Calsolaro

http://www.w3.org/2001/XMLSchema#string

P2860

Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease

Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice.

GLP-1, the gut-brain, and brain-periphery axes

Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease

Insulin neuroprotection and the mechanisms

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling

Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment

P2888

s40263-015-0301-8

P304

1023-1039

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40263-015-0301-8

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287159642

http://www.w3.org/2001/XMLSchema#string

P698

26666230

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

neurodegeneration